Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,495 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neoplasms of the Prostate Clear all
Recruiting Phase 2Phase 3 Interventional

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

NCT06780670
View directory record Official record
Conditions
Prostate Cancer
Interventions
Investigators choice of SoC, AAA817
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • Santa Barbara, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 22, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Results available

PS-341 Followed by Removal of Prostate for Those With Prostate Cancer

NCT00425503
View directory record Official record
Conditions
Prostate Neoplasms
Interventions
PS-341 (bortezomib)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 22, 2026, 1:45 PM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy in Treating Patients With Stage II Prostate Cancer

NCT00331773
View directory record Official record
Conditions
Prostate Cancer
Interventions
Conventional 3D-CRT or IMRT, Hypofractionated 3D-CRT or IMRT
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
1,116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
282
States / cities
Phoenix, Arizona • Tucson, Arizona • Auburn, California + 200 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Jul 22, 2026, 1:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Redes III Patient Navigator Qol Study

NCT02275754
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Colorectal Cancer
Interventions
PN+LCNC, PN Only
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Jul 22, 2026, 1:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

NCT01505868
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Small Cell Carcinoma
Interventions
Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Detroit, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Jul 22, 2026, 1:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

NCT01415960
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Drug
Lead sponsor
GP-Pharm
Industry
Eligibility
18 Years and older · Male only
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
25
States / cities
San Diego, California • Daytona Beach, Florida • Ocala, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 22, 2026, 1:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

NCT02555189
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer AJCC v7
Interventions
Enzalutamide, Ribociclib, Laboratory Biomarker Analysis, Pharmacological Study, Biospecimen Collection, Biopsy, Echocardiography, Multigated Acquisition Scan, Bone Scan, Computed Tomography, Magnetic Resonance Imaging
Drug · Other · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
4
States / cities
Ann Arbor, Michigan • Buffalo, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 22, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Results available

Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

NCT01533246
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
linsitinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Jul 22, 2026, 1:45 PM EDT
Completed Not applicable Interventional

InBody Band 3 Fitness Tracker to Improve Health Outcomes and Quality of Life in Black Prostate Cancer Survivors

NCT06703996
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Discussion, Medical Device Usage and Evaluation, Questionnaire Administration
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Jul 22, 2026, 1:45 PM EDT
Recruiting Phase 2Phase 3 Interventional

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

NCT03495427
View directory record Official record
Conditions
Prostate Cancer, Recurrent Prostate Cancer
Interventions
F-DCFPyL Injection, PSMA PET
Drug · Diagnostic Test
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 22, 2026, 1:45 PM EDT
Terminated Not applicable Interventional

Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy

NCT03574194
View directory record Official record
Conditions
Cancer, Lung Cancer, Prostate Cancer, Breast Cancer
Interventions
Methionine-restricted diet
Dietary Supplement
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Jul 22, 2026, 1:45 PM EDT
Recruiting No phase listed Observational

Phase I Human Analytics (HALO) Study

NCT05423860
View directory record Official record
Conditions
Cardiovascular Diseases, Cancer, Dementia, Traumatic Brain Injury
Interventions
no interventions will be performed (observational)
Other
Lead sponsor
HALO Diagnostics
Industry
Eligibility
45 Years to 90 Years · Male only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
1
States / cities
Indian Wells, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Jul 22, 2026, 1:45 PM EDT
Completed Not applicable Interventional

The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer

NCT00605488
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Prostate Cancer
Interventions
novel PET tracer FACBC
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Jul 22, 2026, 1:45 PM EDT
Completed Not applicable Interventional Results available

Pilot Study to Assess the Safety and Efficacy of BioProtect Balloon in Prostate Cancer Subjects

NCT00918229
View directory record Official record
Conditions
Prostate Cancer
Interventions
balloon implant, Balloon implantation
Device · Procedure
Lead sponsor
BioProtect
Industry
Eligibility
45 Years to 85 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Jul 22, 2026, 1:45 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT04428788
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
CC-94676, CC1083611, CC1083610
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Male only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
19
States / cities
Stanford, California • Washington D.C., District of Columbia • Sarasota, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jul 22, 2026, 1:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

NCT04424641
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC), Squamous Cell Carcinoma of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Bladder Cancer, Uterine Cancer
Interventions
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Jul 22, 2026, 1:45 PM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)

NCT02179515
View directory record Official record
Conditions
Lung Cancer, Breast Cancer, Prostate Cancer, Tumors (Others), Ovarian Cancer
Interventions
MVA-brachyury- TRICOM
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Jul 22, 2026, 1:45 PM EDT
Completed Phase 1 Interventional

Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

NCT00748046
View directory record Official record
Conditions
Prostate Cancer, Metastases, Pharmacokinetics
Interventions
Radium-223 chloride (BAY88-8223)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Jul 22, 2026, 1:45 PM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy

NCT00002874
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, radiation therapy, placebo
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Male only
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2022
U.S. locations
221
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 168 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Jul 22, 2026, 1:45 PM EDT
Completed Phase 2 Interventional

Hormone Therapy Followed By Internal Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer

NCT00032006
View directory record Official record
Conditions
Prostate Cancer
Interventions
brachytherapy, radiation therapy
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Urbana, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jul 22, 2026, 1:45 PM EDT
Completed Phase 4 Interventional

Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis

NCT00035997
View directory record Official record
Conditions
Prostate Cancer
Interventions
Zometa
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
56
States / cities
Birmingham, Alabama • Anchorage, Alaska • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2009 · Synced Jul 22, 2026, 1:45 PM EDT
Completed No phase listed Observational

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)

NCT02380274
View directory record Official record
Conditions
Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Interventions
Not listed
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
148
States / cities
Homewood, Alabama • Anchorage, Alaska • Phoenix, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jul 22, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy

NCT00589420
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, sorafenib tosylate
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Jul 22, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Results available

Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

NCT00390468
View directory record Official record
Conditions
Metastatic Cancer, Pain, Prostate Cancer
Interventions
Tandutinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Jul 22, 2026, 1:45 PM EDT